Niramai is a pioneering brand in the field of breast cancer screening. Their flagship product, Thermalytix, is a computer-aided diagnostic engine that leverages the power of Artificial Intelligence. This innovative solution utilizes a high-resolution thermal sensing device along with a cloud-hosted analytics platform to analyze thermal images for accurate and early breast cancer screening.

Niramai Thermalytix has made tremendous strides in breast cancer detection, with over 100,000 women benefiting from the test across 150+ hospitals and diagnostic centers, as well as 5000+ screening camps in countries like India, UAE, Kenya, Philippines, Sweden, Bulgaria, and Turkey. The test has obtained a CE Mark for all European countries and regulatory clearance in the aforementioned nations. Niramai follows strict quality management processes, certified to be compliant with ISO 13485 and MDSAP standards.

They adhere to good clinical practices, information security protocols, and data privacy policies, as per the requirements of EU GDPR and US HIPAA. Clinical trials have shown that Thermalytix offers exceptional accuracy, with results non-inferior to X-Ray Mammography and a 25% better sensitivity in women with dense breasts. Multiple peer-reviewed studies published in renowned journals support these findings.

With 32 granted patents worldwide, Niramai is at the forefront of innovation in cancer screening. Their mission is to create a universal cancer screening method, saving lives through advanced technology